Massimo Mapelli, Irene Mattavelli, Elisabetta Salvioni, Nicolò Capra, Alice Bonomi, Gaia Cattadori, Beatrice Pezzuto, Jeness Campodonico, Arianna Piotti, Alessandro Nava, Massimo Piepoli, Damiano Magrì, Stefania Paolillo, Ugo Corrà, Rosa Raimondo, Rocco Lagioia, Carlo Vignati, Roberto Badagliacca, Pasquale Perrone Filardi, Michele Senni, Michele Correale, Mariantonietta Cicoira, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Gianfranco Parati, Fabiana De Martino, Francesco Bandera, Maurizio Bussotti, Federica Re, Carlo M Lombardi, Angela B Scardovi, Susanna Sciomer, Andrea Passantino, Michele Emdin, Caterina Santolamazza, Enrico Perna, Claudio Passino, Gianfranco Sinagra, Piergiuseppe Agostoni
INTRODUCTION: Risk stratification in heart failure (HF) is essential for clinical and therapeutic management. The Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score is a validated prognostic model for assessing cardiovascular risk in HF patients with reduced ejection fraction (HFrEF). From the validation of the score, the prevalence of HF patients treated with direct oral anticoagulants (DOACs), such as edoxaban, for non-valvular atrial fibrillation (NVAF) has been increasing in recent years...
December 23, 2023: Journal of Clinical Medicine